Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of…
Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson’s disease patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…